Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions
Latest Information Update: 05 Oct 2021
At a glance
- Drugs BI 2536 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- 03 Jul 2012 Planned number of patients changed from 185 to 220 as reported by European Clinical Trials Database record.
- 08 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
- 04 Oct 2006 New trial record.